Communiqués AptarGroup, Inc.

Actions

ATR

US0383361039

Conteneurs et emballages hors papier

Temps réel estimé Cboe BZX 19:18:05 01/10/2026			Varia. 5j.	Varia. 1 janv.
121,38 ^USD	+0,18%		-1,78%	-0,63%

21/09	La filiale russe d'AptarGroup placée sous le contrôle temporaire de l'État	MT
21/09	La Russie place Aptar Europe Holding sous administration provisoire	RE

Communiqués

14/09	Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery	BU
30/07	AptarGroup: Q2 Earnings Snapshot	AQ
30/07	Aptar Reports Second Quarter 2026 Results	BU
27/07	Aptar Named One of the World's Most Sustainable Companies by TIME for Third Consecutive Year	BU
16/07	Aptar Declares Quarterly Dividend	BU
14/07	Aptar Named Among Top 100 of America's Best Companies by TIME	AQ
13/07	Aptar Named Among Top 100 of America’s Best Companies by TIME	BU
18/06	Aptar Releases 2025 Corporate Sustainability Report	BU
02/06	Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year	BU
27/05	Aptar to Participate in Upcoming Investor Conferences	BU
07/05	Aptar Advances Sustainability Features in Luxury Packaging through Patented Reloadable Airless Innovation with Clarins	AQ
06/05	AptarGroup : 2026 Annual Meeting of Stockholders	PU
01/05	AptarGroup : First Quarter 2026 Historical Financials	PU
30/04	AptarGroup: Q1 Earnings Snapshot	AQ
30/04	Aptar Reports First Quarter 2026 Results	BU
23/04	Aptar Declares Quarterly Dividend	BU
23/04	Aptar Recognized as One of America's Climate Leaders by USA Today for the Fourth Consecutive Year	AQ
22/04	Aptar Recognized as One of America’s Climate Leaders by USA Today for the Fourth Consecutive Year	BU
09/04	Aptar Digital Health Partners with Enable Injections for enFuse(R) Companion Digital Solution	AQ
08/04	Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution	BU
20/03	Aptar's Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA-051 Nasal Spray	AQ
19/03	Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray	BU
17/03	Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year	BU
02/03	AptarGroup : Bank of America 2026 Injectable Drug Packaging Virtual Field Trip	PU
25/02	AptarGroup : Bank of America 2026 Global Agriculture and Materials Conference	PU